CAJ | 학술논문

目的：评价达格列净对2型糖尿病患者血糖及心血管危险因素的影响。方法全面检索Cochrane图书馆、PubMed、EmBase、CNKI、万方数据库及临床试验注册网站，对检索到的随机对照试验进行质量评价，并用RevMan5.2软件进行 Meta 分析。结果共纳入14项试验，7976例患者。Meta分析显示，与安慰剂比较，达格列净可显著降低糖化血红蛋白及空腹血糖水平，可显著降低体重及血压，还可改善血脂水平（ P＜0.01）；而低血糖的发生率相似。结论达格列净可以有效改善2型糖尿病患者的血糖及心血管危险因素。
목적：평개체격렬정대2형당뇨병환자혈당급심혈관위험인소적영향。방법전면검색Cochrane도서관、PubMed、EmBase、CNKI、만방수거고급림상시험주책망참，대검색도적수궤대조시험진행질량평개，병용RevMan5.2연건진행 Meta 분석。결과공납입14항시험，7976례환자。Meta분석현시，여안위제비교，체격렬정가현저강저당화혈홍단백급공복혈당수평，가현저강저체중급혈압，환가개선혈지수평（ P＜0.01）；이저혈당적발생솔상사。결론체격렬정가이유효개선2형당뇨병환자적혈당급심혈관위험인소。
Objective To evaluate the effect of dapagliflozin on hyper-glycaemia and cardiovascular risk factors.Methods Cochrane library , PubMed, EmBase, CNKI, Wanfang database and trial register websites were searched to identify randomized controlled trials ( RCT).The quali-ty of included studies was assessed and Meta -analysis was performed by RevMan5.2.Results Fourteen RCTs involving 7 976 patients were in-cluded.Compared with placebo , dapagliflozin could significantly reduce levels of HbA1c and fasting plasma glucose , significant improvements of body weight , blood pressure , and blood cholesterol were also achieved while the incidences of hypoglycaemia were similar .Conclusion Dapa-gliflozin could significantly improve control of hyperglycaemia and cardio-vascular risk factors in patients with type 2 diabetes.